Investigation the Effect of Montelukast in COVID-19

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT04718285

Recruitment Status : Unknown

Verified April 2022 by Serdar Durdagi, Bahçeşehir University.
Recruitment status was: Recruiting

First Posted : January 22, 2021

Last Update Posted : April 28, 2022

View this study on the modernized ClinicalTrials.gov

Sponsor:

Collaborators:

Medipol University

The Scientific and Technological Research Council of Turkey

Information provided by (Responsible Party):

Serdar Durdagi, Bahçeşehir University

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Unknown
Estimated Primary Completion Date :	May 1, 2022
Estimated Study Completion Date :	June 1, 2022

Publications:

Durdagi S, Avsar T, Orhan MD, Serhatli M, Balcioglu BK, Ozturk HU, Kayabolen A, Cetin Y, Aydinlik S, Bagci-Onder T, Tekin S, Demirci H, Guzel M, Akdemir A, Calis S, Oktay L, Tolu I, Butun YE, Erdemoglu E, Olkan A, Tokay N, Isik S, Ozcan A, Acar E, Buyukkilic S, Yumak Y. The neutralization effect of montelukast on SARS-CoV-2 is shown by multiscale in silico simulations and combined in vitro studies. Mol Ther. 2022 Feb 2;30(2):963-974. doi: 10.1016/j.ymthe.2021.10.014. Epub 2021 Oct 19.

To Top